Antiproliferative, neurotoxic, genotoxic and mutagenic effects of toxic cyanobacterial extracts

Copyright © 2018 SETOX & Institute of Experimental Pharmacology and Toxicology, SASc..

Cyanobacteria are the rich resource of various secondary metabolites including toxins with broad pharmaceutical significance. The aim of this work was to evaluate the antiproliferative, neurotoxic, genotoxic and mutagenic effects of cyanobacterial extracts containing Microcystin-LR (MCLR) in vitro. ELISA analysis results showed that MCLR contents of five cyanobacterial extracts were 2.07 ng/mL, 1.43 ng/mL, 1.41 ng/mL, 1.27 ng/mL, and 1.12 ng/mL for Leptolyngbya sp. SB1, Phormidium sp. SB4, Oscillatoria earlei SB5, Phormidium sp. SB2, Uncultured cyanobacterium, respectively. Phormidium sp. SB4 and Phormidium sp. SB2 extracts had the lowest neurotoxicity (86% and 79% cell viability, respectively) and Oscillatoria earlei SB5 extracts had the highest neurotoxicity (47% cell viability) on PC12 cell at 1000 µg/ml extract concentration. Leptolyngbya sp. SB1 and Phormidium sp. SB2 showed the highest antiproliferative effect (92% and 77% cell death) on HT29 cell. On the other hand, all concentrations of five toxic cyanobacterial extracts induced DNA damage between 3.0% and 1.3% of tail intensity and did not cause any direct mutagenic effect at the 1000 µg/plate cyanobacterial extracts. These results suggest that cyanobacteria-derived MCLR is a promising candidate for development of effective agents against colon cancer.

Medienart:

E-Artikel

Erscheinungsjahr:

2018

Erschienen:

2018

Enthalten in:

Zur Gesamtaufnahme - volume:11

Enthalten in:

Interdisciplinary toxicology - 11(2018), 4 vom: 01. Dez., Seite 267-274

Sprache:

Englisch

Beteiligte Personen:

Andeden, Enver Ersoy [VerfasserIn]
Ozturk, Sahlan [VerfasserIn]
Aslim, Belma [VerfasserIn]

Links:

Volltext

Themen:

Cyanobacteria
HT29 cells
HeLa cells
Journal Article
Microcystin-LR
PC12 cells

Anmerkungen:

Date Revised 01.10.2020

published: Print-Electronic

Citation Status PubMed-not-MEDLINE

doi:

10.2478/intox-2018-0026

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM303651695